title: Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study.
abstract: Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.
authors: University of Cincinnati Medical Center, Barrett Cancer Center, P.O. Box 670501, 45219-0501, USA, Cincinnati, OH, USA
authors: L E.
authors: LE
authors: Schroder
authors: D
authors: D
authors: Lew
authors: R C.
authors: RC
authors: Flanigan
authors: M A.
authors: MA
authors: Eisenberger
authors: T E.
authors: TE
authors: Seay
authors: N
authors: N
authors: Hammond
authors: B M.
authors: BM
authors: Needles
authors: E D.
authors: ED
authors: Crawford